These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1236 related articles for article (PubMed ID: 28225435)

  • 21. Bone involvement in patients with lymphoma: the role of FDG-PET/CT.
    Schaefer NG; Strobel K; Taverna C; Hany TF
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):60-7. PubMed ID: 17021808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
    Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
    Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of
    Albano D; Bosio G; Giubbini R; Bertagna F
    Jpn J Radiol; 2017 Oct; 35(10):574-583. PubMed ID: 28748503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
    Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
    J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging.
    Asenbaum U; Nolz R; Karanikas G; Furtner J; Woitek R; Staudenherz A; Senn D; Raderer M; Weber M; Simonitsch-Klupp I; Mayerhoefer ME
    PLoS One; 2016; 11(10):e0164118. PubMed ID: 27723817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
    Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.
    Zanoni L; Broccoli A; Lambertini A; Pellegrini C; Stefoni V; Lodi F; Fonti C; Nanni C; Zinzani PL; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1661-1671. PubMed ID: 31102000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
    Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
    Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique.
    Guo W; Hao B; Chen HJ; Zhao L; Luo ZM; Wu H; Sun L
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):25-32. PubMed ID: 27444682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
    Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY
    Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
    Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
    Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: A meta-analysis of 23 studies.
    Huang T; Li F; Yan Z; Ma Y; Xiong F; Cai X; Zhang Q; Liu F; Dong J
    Medicine (Baltimore); 2018 Nov; 97(48):e13457. PubMed ID: 30508968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
    Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
    Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.